Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Dexamethasone
Drug: Anisodamine
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Irinotecan
Drug: Bevacizumab

First Posted Date: 2023-02-14

Last Posted Date: 2024-03-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 194

Registration Number: NCT05727163

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer

Phase 1

Recruiting

Conditions: Colon Cancer
Colorectal Cancer

Interventions: Drug: MRTX849
Drug: Irinotecan
Drug: Cetuximab

First Posted Date: 2023-02-10

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05722327

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
BRCA1 Mutation
BRCA2 Mutation
ATM Gene Mutation
PALB2 Gene Mutation

Interventions: Drug: Niraparib
Drug: Irinotecan

First Posted Date: 2023-01-23

Last Posted Date: 2024-12-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 24

Registration Number: NCT05694715

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1

Suspended

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Core Biopsy
Drug: Fluorouracil
Drug: Irinotecan
Drug: Leucovorin
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Quemliclustat
Drug: Zimberelimab

First Posted Date: 2023-01-18

Last Posted Date: 2024-02-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT05688215

Locations: 🇺🇸
Yonemoto,Lisa, Los Angeles, California, United States

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3

Recruiting

Conditions: Clinical Stage III Gastric Cancer AJCC v8
Advanced Esophageal Adenocarcinoma
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Unresectable Esophageal Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Advanced Gastric Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8

Interventions: Drug: Fluorouracil
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Irinotecan
Biological: Nivolumab
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2023-01-10

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 382

Registration Number: NCT05677490

Locations: 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸
Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸
Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States

and more 729 locations

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer Metastatic
Neoplasm, Colorectal
Colorectal Adenocarcinoma
Colorectal Cancer
Colorectal Neoplasms

Interventions: Drug: Fosifloxuridine Nafalbenamide
Drug: Leucovorin
Drug: Irinotecan
Biological: Bevacizumab
Drug: 5-FU

First Posted Date: 2023-01-10

Last Posted Date: 2024-04-03

Lead Sponsor: NuCana plc

Target Recruit Count: 182

Registration Number: NCT05678257

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 56 locations